lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
Published 5 years ago • 2.4K plays • Length 7:03Download video MP4
Download video MP3
Similar videos
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
7:56
keynote-048: progression post next line for r/m hnscc
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
1:18
keynote-048 trial
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
5:16
danny rischin, asco 2019 - phase iii keynote-048 trial
-
11:47
pembrolizumab in hnscc
-
5:48
the impact of systemic therapy and keynote-048 trial
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
2:18
comment on cetuximab versus cisplatin in hpv-positive patients & keynote-048 in r/m hnscc
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
4:46
preliminary results from keynote-055: pembrolizumab in hnscc
-
1:55
dr. burtness on findings of keynote-048 in head and neck cancer
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:52
dr. burtness on promise of frontline pembrolizumab in metastatic hnscc